Compare Global X Cloud Computing ETF (CLOU) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cloud Computing ETF vs Crispr Therapeutics AG — how do they compare? Global X Cloud Computing ETF trades at $27.69, while Crispr Therapeutics AG trades at $53.81 (market cap $5.23B). The key difference: Global X Cloud Computing ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CLOU | CRSP | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $28.09 | $76.78 |
52-Week Low | $17.60 | $44.34 |
Market Cap | — | $5.23B |
Enterprise Value | — | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLOU, the Global X Cloud Computing ETF, trades at $27.83, down 0.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF provides diversified exposure to cloud computing stocks, with top holdings like Snowflake and Datadog showing strong non-AI growth drivers. Recent news highlights long-term growth potential beyond AI hype, supported by customer expansion and resilient subscription revenues.
Outlook remains positive for long-term investors due to structural growth in cloud adoption, though short-term risks include high valuations and sector volatility. Key opportunities lie in business diversification and profitability improvements among holdings, while risks involve competitive pressures and macroeconomic sensitivity affecting tech stocks.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Cloud Computing ETF
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
